I posted this elsewhere but I thought I would share why I am heavily invested in Tyme Technologies:
yes hi I am new. I have been posting the catalysts coming in 2nd half of 2019. About the phase 3 studies I can't believe that investors aren't buying. That's because both the 3rd line from the company, and the 2nd line from PanCAN are allowed to be set up as pivotal according to the FDA. That means with good data Tyme will gain accelerated approval for each study they won't need a phase 3 for approval. I did my DD and I liked everything about the biotech.
For instance)
1.) multiple catalysts in 2nd half of 2019 as I posted in other post, there are about 5 catalysts approaching at any moment in 2019
2,) The CEO and co-founder both each own about 2.64 million shares, which I found refreshing because many biotechs the CEO or insiders never buy or own any shares. It's encouraging that insiders own that many shares it makes me believe that they have confidence in their product.
3,) I liked the way they treat cancer by removing the musin layer that protects it using modified tyrosine and oxidative stress. The science to me is intriguing. By removing the musin layer the cancer cell is exposed and it's defense at that point is weak. Best part of all is that healthy cells in humans don't take up such amino acids like tyrosine, therefore, healthy cells are not affected. That's why there is barely any adverse events in all the studies observed to date.
4,) They are diversifying the pipeline by gearing up TYME-18 for intratumoral injection and then they have other products.
5,) They have already developed proof of concept in prostate cancer and pancreatic cancer. If it was just pancreatic cancer alone then I might be cautious, but since they already shown impressive data in two types of cancer it leads me to believe SM-88 works in treating multiple types of cancer and it has efficacy.
